W. 2001). They do not simply constitute a bidirectional information flow within society, but they also show the problems public opinion is more interested in. The analysis of the ways media deals with current topics can give an idea of how most people perceive and evaluate various issues. Means of communication, together with politics, law and personal opinions expressed in more or less private conversations, belong to the socalled "public sphere" of a country (ibidem).
This research evaluates the ways mass media has dealt with the Human Genome Project in the attempt to define the public image of this great scientific project in different countries. To that end, both quantitative and qualitative analyses have been carried out on five newspapers 1 in four different countries: United States, France, England and Italy. The purpose was to determine:
• the extent of media coverage of the Human Genome Project during its development, and its impact on the media;
• which issues have been discussed and which of them have been illustrated positively or negatively;
• how the two above-mentioned aspects have changed during the years of the Human Genome Project;
• the differences in the communication of this event by the media of various countries (Italy, France, England and the United States). Considering Bauer's definition, the following newspapers have been analysed: the Corriere della Sera and la Repubblica for Italy, Le Monde for France, The Independent for Great Britain and The New York Times for the United States.
Data has been collected both using electronic databases, available on-line and on CD-ROM, and filing the periodicals on microfilms. Unfortunately, data availability was different from newspaper to newspaper. Some of them have digitised information only from a certain date -for instance, the file of the Corriere della Sera starts from January 1992 -or such information is available only on payment -this is the case of The New 1 The definition is by Martin Bauer and it explains the reason of choosing such an analysis. He writes that among all mass media some dailies and magazines are considered to function as a source of information not only for the public, for politicians, manufacturers and operators of different sectors, but also for other media. Analysing the opinion-leading press, we can have both a reasonable and reliable evaluation of the way society elaborates the significance of important issues, and an inside look at how this information flows in time (Bauer M.W. and Gaskell G. 2001 Bauer and Gaskell (Bauer M.W. and Gaskell G. 2001) , has been carried out on the two sample periods.
Quantity analysis
The Human Genome Project: a media event?
Different studies have shown that the media has been increasingly interested in biotechnologies since the seventies (Lewenstein B.V. and Nisbet M.C. 2002; Bauer M. W. 2001; Gaskett G. and Bauer M.W. 2001) . Similarly, subjects relating to genetics and to biomedicine, such as the Human Genome Project, have drawn the attention of the public and they have acquired increasing relevance in newspapers. As early as 1995, an analysis carried out by the University of Tennessee showed that news from the Associated Press Agency relating to the Human Genome Project was increasing.
Year
Number of articles The most specific expression "Human Genome Project" has been used in articles where the international project was the main subject or where it was expressly mentioned in the text. On the contrary, the expression "human genome" has been employed for subjects relating to human genetics, but not in the context of the project. 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 2 0 0 1 1 9 9 0 1 9 9 1 1 9 9 2 1 9 9 3 1 9 9 4 1 9 9 5 1 9 9 6 1 9 9 7 1 9 9 8 1 9 9 9 2 0 0 0 Repubblica from 2 to 8 and the Corriere della Sera from 1 to 3. However, it is essential to remember that Craig Venter founded Celera Genomics exactly in May 1998, challenging the public sector on human genome sequencing (Davies K. 2001) . The monthly distribution of articles in 1998 and in 2000 also proved interesting.
Nyt

QUANTITY ANALYSIS CHARTS
In 1998 
N.B. Monthly distribution data is not available for The
Independent..
Quality analysis Sample
The above-mentioned quantity analysis refers to all ten years of the Human Later, all sample articles have been analysed and catalogued according to purpose-specific parameters. These parameters have been chosen in order to obtain two different types of information. The first evaluation, though not exhaustive, had to determine the importance given by each newspaper to the Human Genome Project and to define the ways the subject had been dealt with. To this end, each article was catalogued according to length, typology, section occupied in the newspaper, and author.
Then, after reading all the articles carefully, their subjects and valence were defined. The following chart shows parameters used to catalogue sample articles. Moreover, the Human Genome Project -above all in the Corriere della Seraappears almost only in news items, and not in finance, culture or society pages.
A difference between the five newspapers lies in the way they have individually The analysis of articles published in June and July 2000 shows great many differences in the importance given to each theme. The New York Times is the only one not to change the way it deals with the human genome when passing from one period to the other. In general, it discusses all themes, whereas in 1998 it focused mainly on scientific description, on relations between public and private research and on financing.
Moreover, the valence, which is clearly positive in the first sample period, becomes more neutral in the second.
As far as Le Monde is concerned, it discusses different themes from May and June 1998 to June and July 2000. The first period focuses on the science frame, especially on scientific description and discovery history, whereas the second deals mainly with patents, commercial exploitation of genetic research results and legal/ethical implications. The valence of each theme also changes. Scientific themes are almost always discussed in a neutral way. On the contrary, commercial exploitation and legal/ ethical implications are no longer described neutrally, but in clearly negative terms.
Actually, France was concerned with patent debate in this second sample period. The
French government, and, in particular, its Minister of Justice, Elisabeth Guigou, disputed the European directive of June 6 1998 relating to the patentability of genetic sequences.
They claimed that France could not implement such a directive because it went counter to national legislation. In 1994 the French bioethical commission had prohibited the marketing of the human body and single body parts 2 , as reported by Le Monde at pages 2 In 1975 molecular biologists met in Asilomar to discuss the potential risks of new techniques of recombinant DNA. They defined protocols to make experiments safer. In a short time, these draft principles were formalized in guidelines issued by the National Institutes of Health and later adopted as self-regulation by all research laboratories using recombinant DNA (Lungagnani V. 2002, pp.6 ff.) . On the contrary, the elaboration of guidelines by the scientific community brought to no laws by the American government and European Community alike. In the nineties, this deficiency in European legislation led to the elaboration of laws considering biological technologies a dangerous activity a priori. In the United States this legislative vacuum was covered by the activity of three federal agencies, In the eighties, within the ambit of OECD (Organization for Economic Cooperation and Development) activity, Europe approved US guidelines, which were meant to foster the marketing of the first biotechnological achievements -i.e. recombinant human insulin and genetically modified seeds. However the European Community had no central watchdog such as the US Federal agencies. Therefore its member countries adopted different emergency regulations on the subject of biotechnologies. Today the harmonization process of such rules has yet to be concluded. 
